HIV Infections Clinical Trial
Official title:
Outcome Evaluation of Minority AIDS Initiative Programs in the New York EMA
This outcome evaluation effort provides the opportunity to learn what programmatic approaches effectively address two of the most difficult hurdles in HIV health services delivery: (1) getting people who would benefit from health care to use it and (2) getting people who do use health care to do so more consistently and effectively. The New York HIV Planning Council (through MHRA) has funded 23 agencies to achieve these objectives for people of color with HIV disease.
Status | Recruiting |
Enrollment | 5100 |
Est. completion date | November 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - HIV-positive - Not in HIV care, or difficulty being maintained in HIV care - HIV-negative but at high risk of HIV infection Exclusion Criteria: - HIV-negative and not at high risk of HIV infection |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Bronx Lebanon Hospital Center | Bronx | New York |
United States | Health Center at Tremont, North Bronx Healthcare Network | Bronx | New York |
United States | Health People | Bronx | New York |
United States | Planned Parenthood of New York City, Project Street Beat | Bronx | New York |
United States | Urban Horizons, The Institute for Urban Family Health | Bronx | New York |
United States | HHC Cumberland Diagnostic and Treatment Center | Brooklyn | New York |
United States | Interfaith Medical Center | Brooklyn | New York |
United States | SUNY Downstate Medical Center | Brooklyn | New York |
United States | Mount Vernon Hospital | Mount Vernon | New York |
United States | African Services Committee | New York | New York |
United States | Bellevue Hospital Center | New York | New York |
United States | Betances Health Center | New York | New York |
United States | Harlem Hospital Center | New York | New York |
United States | New York Harm Reducation Educators, Inc. | New York | New York |
United States | New York Presbyterian Hospital | New York | New York |
United States | Partnership Homeless Services Corp. | New York | New York |
United States | Saint Vincents Hospital and Medical Center | New York | New York |
United States | Settlement Health | New York | New York |
United States | The Bridge, Inc. | New York | New York |
United States | William F. Ryan Community Health Center | New York | New York |
United States | Greyston Health Services, Inc. | Yonkers | New York |
United States | Saint Johns Riverside Hospital, Park Care Pavilion (ATC program) | Yonkers | New York |
United States | Saint Johns Riverside Hospital, Park Care Pavilion (MIC Program) | Yonkers | New York |
Lead Sponsor | Collaborator |
---|---|
The New York Academy of Medicine | Public Health Solutions |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional Health Status (ACTG SF-21): at 3, 6, and 12 mos. | |||
Secondary | Housing stability: at 3, 6, and 12 months | |||
Secondary | Substance use: at 3, 6, and 12 months | |||
Secondary | Whether receiving HIV primary care: at 3, 6, and 12 months | |||
Secondary | Whether on HIV meds: at 3, 6, and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |